Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01107106 · ClinicalTrials.gov registry record
Safety, Tolerability, and Efficacy of ellaOne® (Ulipristal Acetate) for Emergency Contraception in Postmenarcheal Adolescent Girls and Women
A clinical trial of Contraception, sponsored by HRA Pharma.
- Completed
- Registry status
- 579
- Enrollment target
- 6
- Study locations
NCT01107106: Completed study of Contraception, sponsored by HRA Pharma.
NCT01107106 is a study of Contraception that has completed, run by HRA Pharma. The registered enrollment target is 579 participants, above the 447-participant average among 72 other Contraception trials with a reported enrollment target (30% higher). The trial reports 6 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01107106, a study of Contraception, has completed, sponsored by HRA Pharma.
- COMPLETED
- Registry status
- 579 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this observational study is to assess the safety and tolerability of ellaOne® in routine conditions of use for emergency contraception in postmenarcheal adolescents and adult women who want to prevent pregnancy up to 5 days after unprotected sexual intercourse.
Primary Outcome
Collection of adverse events, concomitant treatments, length of menstrual cycle, and vaginal bleeding/spotting through follow-up contacts and a diary completed by the patient
Conditions Studied
Interventions
- DRUG ellaOne® (ulipristal acetate)
Study Locations (6)
Colorado
- PPRM Central clinic - Denver
- PPRM Southwest clinic - Lakewood
Pennsylvania
- Elizabeth Blackwell Health Center - Philadelphia
- Locust Health Center - Philadelphia
Other
- Dept of Women & Child Health - Karolinska University Hospital - Stockholm
- Brook clinic - Belfast
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 579 participants |
| Start Date | 2010-05 |
| Est. Completion | 2013-02 |
What the finished NCT01107106 record still lists
NCT01107106 is an observational study that tracks outcomes without assigning an intervention. The registered 579 participants enrollment target is mid-sized for trials with a published cap, above the 447-participant average among 72 other Contraception trials with a reported enrollment target (30% higher).
The record links to 1 condition, with Contraception appearing as the primary indexed condition, and to 1 intervention - of which ellaOne® (ulipristal acetate) is the first listed.
NCT01107106 lists 6 locations in 3 states (Colorado, Pennsylvania, Other).
Frequently Asked Questions
What is clinical trial NCT01107106 about?
NCT01107106 is a clinical study titled "Safety, Tolerability, and Efficacy of ellaOne® (Ulipristal Acetate) for Emergency Contraception in Postmenarcheal Adolescent Girls and Women". The purpose of this observational study is to assess the safety and tolerability of ellaOne® in routine conditions of use for emergency contraception in postmenarcheal adolescents and adult women who want to prevent pregnancy up to 5 days after unprotected sexual intercourse.
What is the current status of trial NCT01107106?
This trial is currently completed. The enrollment target is 579 participants. The study started on 2010-05. Estimated completion is 2013-02.
What conditions does trial NCT01107106 study?
This clinical trial studies the following conditions: Contraception.
What interventions are being tested in trial NCT01107106?
The interventions under investigation include: ellaOne® (ulipristal acetate) (DRUG).
Who is sponsoring clinical trial NCT01107106?
This trial is sponsored by HRA Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01107106 being conducted?
This trial has 6 study locations across Colorado, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Contraception
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01107106's enrollment target sits among peer trials
579 21st of 72 higher than 52 of 72 other Contraception trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Contraception trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Oral Contraceptive Pill (OCP) Pharmacogenomics
RECRUITING · Phase 4
-
Intravenous Ketorolac Administration to Attenuate Post-procedural Pain Associated With Intrauterine Device Placement
RECRUITING · Phase 4
-
Patient-clinical Linkages to Improve Trust and Engagement in Postpartum Healthcare
RECRUITING · NA
-
Empathy Through Pain Control: Lidocaine Paracervical Block for IUD Placements
RECRUITING · NA
-
Hormonal Contraception Access Through Pharmacist Prescribing Implementation
RECRUITING · NA
-
Prospective Multi-Center Trial for FemBloc Permanent Birth Control
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04575935 · 580 participants · Phase 3
Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
- NCT05143177 · 580 participants · Phase 2
A Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease With Mild to Moderate Aortic Stenosis (EVOID-AS)
- NCT05696353 · 580 participants · Phase 3
Teen Driving Translation Study (NIH)
- NCT06578104 · 580 participants
PULSED AF Post-Approval Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia